Zandelisib

SKU: orb1308922

Description

Zandelisib is a potent and selective PI3K p110δ inhibitor (IC50 = 3.5 nM) with demonstrated antineoplastic activity. It is used in research for studying B-cell malignancies, both in vitro and in preclinical in vivo models, to investigate targeted oncology therapies.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1401436-95-0
• MW: 576.68
• Purity: 99.88% (May vary between batches)
• Formula: C₃₁H₃₈F₂N₈O
• SMILES: CN1CCC(CC1)c1ccccc1CC(C)(C)Nc1nc(nc(n1)-n1c(nc2ccccc12)C(F)F)N1CCOCC1
• Target: PI3K
• Solubility: DMSO:33.33 mg/mL (57.8 mM);10% DMSO+90% Corn Oil:2 mg/mL (3.47 mM)

Bioactivity

• Target IC50:
  PI3Kδ:3.5 nM
• In Vitro:
  Zandelisib inhibits PI3Ks(p110α, p110β, p110γ and p110δ with IC50s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM, respectivey).

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, ME 401, ME401, ME-401, Inhibitor, antineoplastic, 3-kinase, PWT143, PWT 143, PWT-143, p110δ, Phosphatidylinositol, Phosphoinositide 3-kinase, PI3K, PI3Kδ, Zandelisib

Compound Identifiers

PubChem CID

66571003